NCT06858878: An ongoing trial by Amgen
This trial is ongoing. It must report results 2 years, 1 month from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06858878 |
|---|---|
| Title | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 17, 2025 |
| Completion date | Jan. 30, 2027 |
| Required reporting date | Jan. 30, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |